Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDA) is among the most lethal human cancers in part because it is insensitive to many chemotherapeutic drugs. Studying a mouse model of PDA that is refractory to the clinically used drug gemcitabine, we found that the tumors in this model were poorly perfused and poorly vascularized, properties that are shared with human PDA. We tested whether the delivery and efficacy of gemcitabine in the mice could be improved by coadministration of IPI-926, a drug that depletes tumor-associated stromal tissue by inhibition of the Hedgehog cellular signaling pathway. The combination therapy produced a transient increase in intratumoral vascular density and intratumoral concentration of gemcitabine, leading to transient stabilization of disease. Thus, inefficient drug delivery may be an important contributor to chemoresistance in pancreatic cancer.

Citing Articles

Mechanical forces in the tumor microenvironment: roles, pathways, and therapeutic approaches.

Zhang Y, Fu Q, Sun W, Yue Q, He P, Niu D J Transl Med. 2025; 23(1):313.

PMID: 40075523 PMC: 11899831. DOI: 10.1186/s12967-025-06306-8.

Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis.

Chambers C, Watakul S, Schofield P, Howell A, Zhu J, Tran A Sci Adv. 2025; 11(11):eadq4416.

PMID: 40073121 PMC: 11900870. DOI: 10.1126/sciadv.adq4416.

Multiplexed base editing identifies functional gene-variant-context interactions.

Acosta J, Johnson G, Gould S, Dong K, Lendner Y, Detres D bioRxiv. 2025; .

PMID: 40060482 PMC: 11888363. DOI: 10.1101/2025.02.23.639770.

Notch and Hedgehog Signaling Unveiled: Crosstalk, Roles, and Breakthroughs in Cancer Stem Cell Research.

Iluta S, Nistor M, Buruiana S, Dima D Life (Basel). 2025; 15(2).

PMID: 40003637 PMC: 11856057. DOI: 10.3390/life15020228.

Retinoic acid receptor-β deletion in a model of early pancreatic ductal adenocarcinoma (PDAC) tumorigenesis.

Mere Del Aguila E, Tang X, Gudas L Am J Cancer Res. 2025; 15(1):127-140.

PMID: 39949931 PMC: 11815370. DOI: 10.62347/XFOT8509.

References

Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R . Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003; 21(18):3402-8. DOI: 10.1200/JCO.2003.09.140. View

Abbruzzese J, Grunewald R, WEEKS E, Gravel D, Adams T, Nowak B . A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991; 9(3):491-8. DOI: 10.1200/JCO.1991.9.3.491. View

Verma A, Guha S, Diagaradjane P, Kunnumakkara A, Sanguino A, Lopez-Berestein G . Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008; 14(8):2476-83. DOI: 10.1158/1078-0432.CCR-07-4529. View

Hingorani S, Wang L, Multani A, Combs C, Deramaudt T, Hruban R . Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005; 7(5):469-83. DOI: 10.1016/j.ccr.2005.04.023. View

Sofuni A, Iijima H, Moriyasu F, Nakayama D, Shimizu M, Nakamura K . Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol. 2005; 40(5):518-25. DOI: 10.1007/s00535-005-1578-z. View

Thayer S, Pasca di Magliano M, Heiser P, Nielsen C, Roberts D, Lauwers G . Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003; 425(6960):851-6. PMC: 3688051. DOI: 10.1038/nature02009. View

Pola R, Ling L, Silver M, Corbley M, Kearney M, Pepinsky R . The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med. 2001; 7(6):706-11. DOI: 10.1038/89083. View

Yauch R, Gould S, Scales S, Tang T, Tian H, Ahn C . A paracrine requirement for hedgehog signalling in cancer. Nature. 2008; 455(7211):406-10. DOI: 10.1038/nature07275. View

Duan J, Jiao H, Kaizerman J, Stanton T, Evans J, Lan L . Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008; 51(8):2412-20. DOI: 10.1021/jm701028q. View

10.

Nolan-Stevaux O, Lau J, Truitt M, Chu G, Hebrok M, Fernandez-Zapico M . GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009; 23(1):24-36. PMC: 2632164. DOI: 10.1101/gad.1753809. View

11.

Schultz R, Merriman R, Toth J, Zimmermann J, Hertel L, Andis S . Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res. 1993; 5(6-7):223-8. View

12.

Egorin M, Hildebrand R, Cimino E, Bachur N . Cytofluorescence localization of adriamycin and daunorubicin. Cancer Res. 1974; 34(9):2243-5. View

13.

Minchinton A, Tannock I . Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583-92. DOI: 10.1038/nrc1893. View

14.

Johnson J, Decker S, Zaharevitz D, Rubinstein L, Venditti J, SCHEPARTZ S . Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001; 84(10):1424-31. PMC: 2363645. DOI: 10.1054/bjoc.2001.1796. View

15.

Langer S, Ghafoori A, Byrd M, Leinwand L . A genetic screen identifies novel non-compatible loxP sites. Nucleic Acids Res. 2002; 30(14):3067-77. PMC: 135742. DOI: 10.1093/nar/gkf421. View

16.

Sakamoto H, Kitano M, Suetomi Y, Maekawa K, Takeyama Y, Kudo M . Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas. Ultrasound Med Biol. 2007; 34(4):525-32. DOI: 10.1016/j.ultrasmedbio.2007.09.018. View

17.

Melisi D, Ishiyama S, Sclabas G, Fleming J, Xia Q, Tortora G . LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008; 7(4):829-40. PMC: 3088432. DOI: 10.1158/1535-7163.MCT-07-0337. View

18.

Bruns C, Shrader M, Harbison M, Portera C, Solorzano C, Jauch K . Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer. 2002; 102(2):101-8. DOI: 10.1002/ijc.10681. View

19.

Tredan O, Galmarini C, Patel K, Tannock I . Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007; 99(19):1441-54. DOI: 10.1093/jnci/djm135. View

20.

Burris 3rd H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6):2403-13. DOI: 10.1200/JCO.1997.15.6.2403. View